Preclinical News and Research

RSS

Research finding could lead to new therapies for malignant glioma

Targeted therapies are a growing and groundbreaking field in cancer care in which drugs or other substances are designed to interfere with genes or molecules that control the growth and survival of cancer cells. Now, scientists at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have identified a novel interaction between a microRNA and a gene that could lead to new therapies for the most common and deadly form of brain tumor, malignant glioma.

12 Dec 2014

Scientists to explore biology of human asthma by using slime mould

Scientists from Royal Holloway, University of London, will research the biology of human asthma by using a slime mould, an organism which has no lungs but could hold the key to new treatments.

12 Dec 2014

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study led by researchers from Boston Children's Hospital, The Children's Hospital at Montefiore, and Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

10 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

$Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors$

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors.

9 Dec 2014

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies.

9 Dec 2014

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials.

9 Dec 2014

PRM-151 compound shows positive results for treating advanced myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

8 Dec 2014

New fluorescence-imaging agent could improve diagnosis, guide surgeons during tumor removal

CEA-Leti and CLARA today announced the development of a new fluorescence-imaging agent that could significantly increase surgeons’ accuracy when removing cancerous tumors.

8 Dec 2014

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.

8 Dec 2014

Study: PET scanning strategy could help predict effectiveness of TB drugs

Sophisticated lung imaging can show whether or not a treatment drug is able to clear tuberculosis (TB) lung infection in human and macaque studies, according to researchers at the University of Pittsburgh School of Medicine and their international collaborators.

5 Dec 2014

Melbourne researcher wins Sornchai Looareesuwan Medal for research on malaria

Melbourne researcher Professor Alan Cowman has won the Sornchai Looareesuwan Medal 2014 for his significant contributions to understanding how the malaria parasite causes disease and for his search for potential malaria vaccines.

4 Dec 2014

Thomson Reuters, Linguamatics launch Cortellis Informatics Clinical Text Analytics for I2E

The Intellectual Property & Science business of Thomson Reuters, the world leader in intelligent information for businesses and professionals, today announced a collaboration with Linguamatics to advance pharmaceutical clinical trial research and development (R&D) with the launch of Cortellis Informatics Clinical Text Analytics for I2E.

4 Dec 2014

UAB research suggests potential therapeutic target for patients with frontotemporal dementia

Drugs that boost the function of a specific type of neurotransmitter receptor may provide benefit to patients with the second most common type of dementia, according to research by scientists at the University of Alabama at Birmingham published today in the Journal of Neuroscience.

4 Dec 2014

Advanced prebiotic Bimuno has ability to reduce anxiety

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno (B-GOS), a unique trans-galactooligosaccharide, and the Department of Psychiatry, University of Oxford, today announce the results of clinical research demonstrating for the first time that an advanced prebiotic (Bimuno) has the ability to reduce anxiety.

4 Dec 2014

Experts report three key topics that may make difference in the battle against Alzheimer's disease

Detection, prevention, and preclinical treatment are three key areas that may make a difference in the battle to reduce the rapid rise of new Alzheimer's disease (AD) cases every year. These three topics are the focus of an important new supplement to the Journal of Alzheimer's Disease.

3 Dec 2014

Neuroimaging markers have synergistic effect on cognitive decline

The Alzheimer disease neuroimaging markers β-amyloid and neurodegeneration have synergistic effects on the rate of cognitive decline in clinically normal people, research shows.

2 Dec 2014

BWH researchers identify cells responsible for fibrosis

Researchers from Brigham and Women's Hospital have identified what they believe to be the cells responsible for fibrosis, the buildup of scar tissue. Fibrotic diseases, such as chronic kidney disease and failure, lung disease, heart failure and cirrhosis of the liver, are estimated to be responsible for up to 45 percent of deaths in the developed world.

2 Dec 2014

Preclinical News and Research

Research finding could lead to new therapies for malignant glioma

Scientists to explore biology of human asthma by using slime mould

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Triple hormone reduces body weight, improves insulin sensitivity

PRM-151 compound shows positive results for treating advanced myelofibrosis

New fluorescence-imaging agent could improve diagnosis, guide surgeons during tumor removal

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

Oral targeted drug shows encouraging activity in patients with relapsed or resistant AML

Study: PET scanning strategy could help predict effectiveness of TB drugs

Melbourne researcher wins Sornchai Looareesuwan Medal for research on malaria

Thomson Reuters, Linguamatics launch Cortellis Informatics Clinical Text Analytics for I2E

UAB research suggests potential therapeutic target for patients with frontotemporal dementia

Advanced prebiotic Bimuno has ability to reduce anxiety

Experts report three key topics that may make difference in the battle against Alzheimer's disease

Neuroimaging markers have synergistic effect on cognitive decline

BWH researchers identify cells responsible for fibrosis

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics